Show simple item record

Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

dc.contributor.authorCIFTCI, Rumeysa
dc.contributor.authorPala-Kara, Zeliha
dc.contributor.authorKaytan-Saglam, Esra
dc.contributor.authorPILANCI, Kezban Nur
dc.contributor.authorOkyar, Alper
dc.contributor.authorSaglam, Sezer
dc.contributor.authorYÜCEL, Serap
dc.contributor.authorOrdu, Cetin
dc.contributor.authorNamal, Esat
dc.contributor.authorIner-Koksal, Ulkuhan
dc.date.accessioned2021-03-06T21:18:43Z
dc.date.available2021-03-06T21:18:43Z
dc.date.issued2016
dc.identifier.citationPILANCI K. N. , Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., Namal E., CIFTCI R., Iner-Koksal U., Kaytan-Saglam E., "Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study", CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.78, ss.143-150, 2016
dc.identifier.issn0344-5704
dc.identifier.othervv_1032021
dc.identifier.otherav_fe1b2996-efcc-4aa1-9e19-3257e2b3502b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/166200
dc.identifier.urihttps://doi.org/10.1007/s00280-016-3067-x
dc.description.abstractThe aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleChronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
dc.typeMakale
dc.relation.journalCANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.contributor.departmentİstanbul Bilim Üniversitesi , ,
dc.identifier.volume78
dc.identifier.issue1
dc.identifier.startpage143
dc.identifier.endpage150
dc.contributor.firstauthorID70458


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record